Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress

Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging

(2017) James K. Lui et al.   JOURNAL OF ALZHEIMERS DISEASE

Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort

(2016) Jeffrey L. Dage et al.   Alzheimers & Dementia

Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals

(2016) Ramon Casanova et al.   Alzheimers & Dementia

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum

(2016) Carlo Wilke et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Network-driven plasma proteomics expose molecular changes in the Alzheimer’s brain

(2016) Philipp A. Jaeger et al.   Molecular Neurodegeneration

Increased CSF neurogranin concentration is specific to Alzheimer disease

(2016) Henrietta Wellington et al.   NEUROLOGY

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

(2016) Jonathan D. Rohrer et al.   NEUROLOGY

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

(2016) Mehtap Bacioglu et al.   NEURON

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis

(2015) Ross W. Paterson et al.   JOURNAL OF NEUROLOGY

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

(2015) Wendy E. Heywood et al.   Molecular Neurodegeneration

Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

(2014) Martina Sattlecker et al.   Alzheimers & Dementia

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

(2014) Kristin R Wildsmith et al.   Molecular Neurodegeneration

Plasma phospholipids identify antecedent memory impairment in older adults

(2014) Mark Mapstone et al.   NATURE MEDICINE

Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease

(2013) Ming-Jang Chiu et al.   ACS Chemical Neuroscience

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

(2013) Carole S. Scherling et al.   ANNALS OF NEUROLOGY

Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma

(2013) Sanna Neselius et al.   BRAIN INJURY

Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease

(2013) Ming-Jang Chiu et al.   HUMAN BRAIN MAPPING

The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease

(2013) Tao Wang et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics

(2013) Eugenia Trushina et al.   PLoS One

Plasma tau levels in Alzheimer's disease

(2013) Henrik Zetterberg et al.   Alzheimers Research & Therapy

Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients

(2012) Michal J. Figurski et al.   Alzheimers & Dementia

β-Amyloid Dynamics in Human Plasma

(2012) Yafei Huang et al.   ARCHIVES OF NEUROLOGY

Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease

(2012) James D. Doecke   ARCHIVES OF NEUROLOGY

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease

(2012) W. T. Hu et al.   NEUROLOGY

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease

(2012) Maria Björkqvist et al.   PLoS One

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

(2011) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Clifford R. Jack et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Plasma A  and PET PiB binding are inversely related in mild cognitive impairment

(2011) D. P. Devanand et al.   NEUROLOGY

Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics

(2010) A.C. Kroksveen et al.   Journal of Proteomics

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels

(2009) Holly D. Soares et al.   Annals of the New York Academy of Sciences

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

(2009) Tero Tapiola et al.   ARCHIVES OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

No correlation between time-linked plasma and CSF Aβ levels

(2009) Nathalie Le Bastard et al.   NEUROCHEMISTRY INTERNATIONAL

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

(2008) Oskar Hansson et al.   NEUROBIOLOGY OF AGING